Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect

Georgalas, Ilias; Pavésio, Carlos; Ezra, Eric

doi:10.1007/s00417-007-0600-y

Cited by 25 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Resolution of the chronic myeloid leukaemia with bone marrow transplantation is associated with resolution of the macular oedema. In some cases, imatinib therapy has been itself associated with the development of cystoid macular oedema …”

Section: Discussionmentioning

confidence: 99%

Reduced vision in a diabetic patient due to incidental leukaemic retinopathy

Tsiamita

Siempis

Varikkara

2019

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Reduced vision in a diabetic patient due to incidental leukaemic retinopathy

Tsiamita

Siempis

Varikkara

2019

Clinical and Experimental Optometry

View full text Add to dashboard Cite

“…25,28 Retinal hemorrhage and macular edema have also been associated with imantinib. 25,85,86 Figure 4 Distinct mechanisms of small-molecule inhibitors and monoclonal antibodies for targeting receptor tyrosine kinases in cancer cells. (a).…”

Section: Vascular Endothelial Growth Factor Receptor Inhibitorsmentioning

confidence: 99%

“…95 Systemic corticosteroids have been used for cases of macular edema and optic neuritis. 85,87 The subretinal fluid associated with the MEK inhibitors can sometimes resolve spontaneously without interrupting therapy. 111 Weber et al 98 recommend continuing MEK inhibitors if subretinal fluid is present because in the majority of cases the visual symptoms are mild and transient.…”

Section: Treatmentmentioning

confidence: 99%

Neuro-ophthalmic side effects of molecularly targeted cancer drugs

Bhatti

Salama

2017

Eye

View full text Add to dashboard Cite

The past two decades has been an amazing time in the advancement of cancer treatment. Molecularly targeted therapy is a concept in which specific cellular molecules (overexpressed, mutationally activated, or selectively expressed proteins) are manipulated in an advantageous manner to decrease the transformation, proliferation, and/or survival of cancer cells. In addition, increased knowledge of the role of the immune system in carcinogenesis has led to the development of immune checkpoint inhibitors to restore and enhance cellular-mediated antitumor immunity. The United States Food and Drug Administration approval of the chimeric monoclonal antibody (mAb) rituximab in 1997 for the treatment of B cell non-Hodgkin lymphoma ushered in a new era of targeted therapy for cancer. A year later, trastuzumab, a humanized mAb, was approved for patients with breast cancer. In 2001, imatinib was the first small-molecule kinase inhibitor approved. The approval of ipilimumab-the first in class immune checkpoint inhibitor-in 2011 serves as a landmark period of time in the resurgence of immunotherapy for cancer. Despite the notion that increased tumor specificity results in decreased complications, toxicity remains a major hurdle in the development and implementation of many of the targeted anticancer drugs. This article will provide an overview of the current cellular and immunological understanding of cancer pathogenesis-the foundation upon which molecularly targeted therapies were developed-and a description of the ocular and neuro-ophthalmic toxicity profile of mAbs, immune checkpoint inhibitors, and small-molecule kinase inhibitors.

show abstract

“…5 Cystoid macular edema is an infrequent ocular side effect, which has been seen in two separate cases. 6 visual loss improved upon discontinuation of imatinib mesylate, there is concern for secondary irreversible visual loss if this therapy is continued. 6 In our survey of the literature and the US Food & Drug Administration Web site, we did not find any reports of macular ischemia associated with imatinib mesylate.…”

mentioning

confidence: 95%

“…6 visual loss improved upon discontinuation of imatinib mesylate, there is concern for secondary irreversible visual loss if this therapy is continued. 6 In our survey of the literature and the US Food & Drug Administration Web site, we did not find any reports of macular ischemia associated with imatinib mesylate. We describe a patient with CML who was treated with imatinib mesylate who had retinal microvascular angiopathy, a previously unreported adverse effect of this treatment.…”

mentioning

confidence: 95%